Atlanta Consulting Group Advisors LLC purchased a new stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 14,342 shares of the biopharmaceutical company's stock, valued at approximately $1,202,000.
A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in GILD. Manning & Napier Advisors LLC acquired a new stake in shares of Gilead Sciences during the second quarter worth approximately $25,328,000. Legal & General Group Plc grew its stake in Gilead Sciences by 0.8% in the second quarter. Legal & General Group Plc now owns 12,414,268 shares of the biopharmaceutical company's stock valued at $851,743,000 after purchasing an additional 93,068 shares in the last quarter. IRON Financial LLC purchased a new stake in shares of Gilead Sciences during the 3rd quarter worth about $830,000. Wealth Enhancement Advisory Services LLC grew its stake in shares of Gilead Sciences by 13.1% in the 2nd quarter. Wealth Enhancement Advisory Services LLC now owns 286,116 shares of the biopharmaceutical company's stock valued at $19,630,000 after buying an additional 33,162 shares in the last quarter. Finally, Cetera Investment Advisers raised its position in Gilead Sciences by 127.6% during the first quarter. Cetera Investment Advisers now owns 213,901 shares of the biopharmaceutical company's stock valued at $15,668,000 after acquiring an additional 119,909 shares in the last quarter. Institutional investors and hedge funds own 83.67% of the company's stock.
Gilead Sciences Trading Down 4.0 %
Shares of GILD stock traded down $3.71 on Friday, hitting $88.40. The stock had a trading volume of 11,454,518 shares, compared to its average volume of 6,971,457. The company has a current ratio of 1.26, a quick ratio of 0.82 and a debt-to-equity ratio of 1.24. Gilead Sciences, Inc. has a twelve month low of $62.07 and a twelve month high of $98.90. The company has a fifty day moving average price of $86.68 and a two-hundred day moving average price of $76.04. The firm has a market cap of $110.17 billion, a P/E ratio of 982.22, a PEG ratio of 2.72 and a beta of 0.17.
Gilead Sciences (NASDAQ:GILD - Get Free Report) last issued its quarterly earnings data on Wednesday, November 6th. The biopharmaceutical company reported $2.02 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.58 by $0.44. Gilead Sciences had a return on equity of 29.00% and a net margin of 0.45%. The business had revenue of $7.55 billion during the quarter, compared to analyst estimates of $7.01 billion. During the same period in the previous year, the firm earned $2.29 EPS. Gilead Sciences's quarterly revenue was up 7.0% compared to the same quarter last year. As a group, analysts forecast that Gilead Sciences, Inc. will post 4.38 earnings per share for the current fiscal year.
Gilead Sciences Announces Dividend
The firm also recently announced a quarterly dividend, which will be paid on Monday, December 30th. Investors of record on Friday, December 13th will be given a $0.77 dividend. This represents a $3.08 dividend on an annualized basis and a yield of 3.48%. The ex-dividend date is Friday, December 13th. Gilead Sciences's dividend payout ratio (DPR) is currently 3,422.22%.
Insider Buying and Selling at Gilead Sciences
In other Gilead Sciences news, insider Merdad Parsey sold 2,000 shares of the firm's stock in a transaction on Tuesday, October 1st. The stock was sold at an average price of $83.83, for a total transaction of $167,660.00. Following the completion of the sale, the insider now owns 100,189 shares of the company's stock, valued at $8,398,843.87. This trade represents a 1.96 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Johanna Mercier sold 29,357 shares of the business's stock in a transaction that occurred on Thursday, September 12th. The shares were sold at an average price of $83.78, for a total value of $2,459,529.46. Following the completion of the sale, the insider now owns 78,127 shares of the company's stock, valued at approximately $6,545,480.06. This trade represents a 27.31 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 56,947 shares of company stock worth $4,968,674. Insiders own 0.16% of the company's stock.
Wall Street Analysts Forecast Growth
Several research analysts have recently issued reports on GILD shares. Leerink Partnrs upgraded shares of Gilead Sciences from a "hold" rating to a "strong-buy" rating in a report on Monday, October 21st. Evercore ISI raised Gilead Sciences to a "strong-buy" rating in a report on Friday, August 9th. The Goldman Sachs Group lifted their price objective on Gilead Sciences from $74.00 to $84.00 and gave the stock a "neutral" rating in a report on Thursday, November 7th. Maxim Group cut Gilead Sciences from a "buy" rating to a "hold" rating in a research report on Friday, November 8th. Finally, BMO Capital Markets raised their target price on Gilead Sciences from $94.00 to $102.00 and gave the stock an "outperform" rating in a research report on Thursday, November 7th. Eleven equities research analysts have rated the stock with a hold rating, eleven have given a buy rating and four have given a strong buy rating to the company. Based on data from MarketBeat.com, Gilead Sciences has an average rating of "Moderate Buy" and a consensus target price of $93.86.
Check Out Our Latest Report on GILD
About Gilead Sciences
(
Free Report)
Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.
Further Reading
Before you consider Gilead Sciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Gilead Sciences wasn't on the list.
While Gilead Sciences currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.
Get This Free Report
